1
|
Gómez-Farto A, Jiménez-Escobar AL, Pérez-González N, Castán H, Clares B, Arias-Santiago S, Montero-Vílchez T. Development of an Emulgel for the Effective Treatment of Atopic Dermatitis: Biocompatibility and Clinical Investigation. Gels 2024; 10:370. [PMID: 38920917 PMCID: PMC11202525 DOI: 10.3390/gels10060370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2024] [Revised: 05/19/2024] [Accepted: 05/21/2024] [Indexed: 06/27/2024] Open
Abstract
Atopic dermatitis (AD) is a common dermatological disease affecting both children and adults. No drug-free emulgel has been developed and studied in vitro and in vivo for the treatment of AD. The aim of this study was to develop and assess the efficacy of a topical emulgel containing hyaluronic acid, glycerol, Calendula officinalis, Aloe vera, polyphenols and EGF for the concomitant treatment in patients with AD aged over 14. Objective skin barrier function parameters were included, such as transepidermal water loss (TEWL), skin temperature, pH, stratum corneum hydration, skin elasticity and erythema. The subjective opinion of the patients was determined including acceptability, absorption, comfort of use and tolerability, as well as the degree of improvement in patients' quality of life. We observed an improvement in the subjective parameters studied and statistically significant differences in the objective parameters. Specifically, we found an improvement in TEWL (p = 0.006), erythema (p = 0.008) and hydration (p < 0.001), parameters indicating an improvement in the epidermal barrier. One hundred per cent of patients were satisfied with the product. Therefore, these results suggest that the product may contribute to the treatment of AD.
Collapse
Affiliation(s)
- Almudena Gómez-Farto
- Instituto de Investigación Biotecnológica, Farmacéutica y Medicamentos Huérfanos, S.L, 18016 Granada, Spain; (A.G.-F.); (A.L.J.-E.); (N.P.-G.); (H.C.)
- Department of Pharmacy & Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, 18071 Granada, Spain
| | - Ana Leticia Jiménez-Escobar
- Instituto de Investigación Biotecnológica, Farmacéutica y Medicamentos Huérfanos, S.L, 18016 Granada, Spain; (A.G.-F.); (A.L.J.-E.); (N.P.-G.); (H.C.)
- Department of Pharmacy & Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, 18071 Granada, Spain
| | - Noelia Pérez-González
- Instituto de Investigación Biotecnológica, Farmacéutica y Medicamentos Huérfanos, S.L, 18016 Granada, Spain; (A.G.-F.); (A.L.J.-E.); (N.P.-G.); (H.C.)
- Department of Pharmacy & Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, 18071 Granada, Spain
| | - Herminia Castán
- Instituto de Investigación Biotecnológica, Farmacéutica y Medicamentos Huérfanos, S.L, 18016 Granada, Spain; (A.G.-F.); (A.L.J.-E.); (N.P.-G.); (H.C.)
- Department of Pharmacy & Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, 18071 Granada, Spain
| | - Beatriz Clares
- Department of Pharmacy & Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, 18071 Granada, Spain
- Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain
- Biosanitary Institute of Granada (ibs.GRANADA), 18012 Granada, Spain; (S.A.-S.); (T.M.-V.)
| | - Salvador Arias-Santiago
- Biosanitary Institute of Granada (ibs.GRANADA), 18012 Granada, Spain; (S.A.-S.); (T.M.-V.)
- Department of Dermatology, Granada School of Medicine, Granada University, Virgen de las Nieves University Hospital, 18012 Granada, Spain
| | - Trinidad Montero-Vílchez
- Biosanitary Institute of Granada (ibs.GRANADA), 18012 Granada, Spain; (S.A.-S.); (T.M.-V.)
- Department of Dermatology, Granada School of Medicine, Granada University, Virgen de las Nieves University Hospital, 18012 Granada, Spain
| |
Collapse
|
2
|
Lu D, Wang W, Li X, Wang L, Guo Y, Zhu C, Wang X, Lian B, Bai J, Zhang Q. Identification and characterization of a PL35 GAGs lyase with 4-O-sulfated N-acetylgalactosamine (A-type)-rich structures producing property. Int J Biol Macromol 2024; 266:131283. [PMID: 38561119 DOI: 10.1016/j.ijbiomac.2024.131283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Revised: 03/18/2024] [Accepted: 03/29/2024] [Indexed: 04/04/2024]
Abstract
Glycosaminoglycan (GAG) lyases are important tools for investigating the structure of GAGs and preparing low-molecular-weight GAGs. The PL35 family, a recently established polysaccharide lyase family, should be further investigated. In this study, we discovered a new GAG lyase, CHa1, which belongs to the PL35 family. When expressed heterologously in Escherichia coli (BL21), CHa1 exhibited high expression levels and solubility. The optimal activity was observed in Tris-HCl buffer (pH 7.0) or sodium phosphate buffer (pH 8.0) at 30 °C. The specific activities towards HA, CSA, CSC, CSD, CSE, and HS were 3.81, 13.03, 36.47, 18.46, 6.46, and 0.50 U/mg protein, respectively. CHa1 digests substrate chains randomly that acting as an endolytic lyase and shows a significant preference for GlcA-containing structures, prefers larger oligosaccharides (≥UDP8) and can generate a series of oligosaccharides composed mainly of the A unit when digesting CSA. These oligosaccharides include ΔC-A, ΔC-A-A, ΔC-A-A-A, ΔC-A-A-A-A, and ΔC-A-A-A-A-A. The residues Tyr257 and His421 play crucial roles in the catalytic process, and Ser211, Asn212, Asn213, Trp214, Gln216, Lys360, Arg460 and Gln462 may participate in the binding process of CHa1. This study on CHa1 contributes to our understanding of the PL35 family and provides valuable tools for investigating the structure of GAGs.
Collapse
Affiliation(s)
- Danrong Lu
- School of Life Science and Technology, Shandong Second Medical University, 7166 Baotong West Street, Weifang 261053, China
| | - Wenwen Wang
- School of Life Science and Technology, Shandong Second Medical University, 7166 Baotong West Street, Weifang 261053, China
| | - Xiaoyun Li
- School of Life Science and Technology, Shandong Second Medical University, 7166 Baotong West Street, Weifang 261053, China
| | - Luping Wang
- School of Life Science and Technology, Shandong Second Medical University, 7166 Baotong West Street, Weifang 261053, China
| | - Yankai Guo
- School of Life Science and Technology, Shandong Second Medical University, 7166 Baotong West Street, Weifang 261053, China
| | - Changjian Zhu
- School of Life Science and Technology, Shandong Second Medical University, 7166 Baotong West Street, Weifang 261053, China
| | - Xiaohui Wang
- School of Life Science and Technology, Shandong Second Medical University, 7166 Baotong West Street, Weifang 261053, China
| | - Bo Lian
- School of Life Science and Technology, Shandong Second Medical University, 7166 Baotong West Street, Weifang 261053, China
| | - Jingkun Bai
- School of Life Science and Technology, Shandong Second Medical University, 7166 Baotong West Street, Weifang 261053, China.
| | - Qingdong Zhang
- School of Life Science and Technology, Shandong Second Medical University, 7166 Baotong West Street, Weifang 261053, China.
| |
Collapse
|
3
|
Trinh TT, Choi JH, Yang J, Kim WH, Chien PN, Le LTT, Ngan‐Giang N, Nga PT, Nam S, Heo C. Effects on keratinocytes of the traditional combination of herb extract (Royal Oji Complex) implicated the improvement of young children's skin moisture and barrier. Skin Res Technol 2024; 30:e13682. [PMID: 38616504 PMCID: PMC11016816 DOI: 10.1111/srt.13682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Accepted: 03/16/2024] [Indexed: 04/16/2024]
Abstract
BACKGROUND Natural products are often friendly and can be used on children's skin after systematic and careful research. Therefore, in this study, the Royal Oji Complex (ROC), a product with natural ingredients, was used to study their effectiveness on keratinocytes taken from the skin of children from 0 to 3 years old. METHOD Normal human epidermal keratinocytes and tissue-isolated keratinocytes (TIKC) from young donors were treated with three different concentrations of ROC: 0.1, 1, and 10 ppm. The mRNA expression of the epidermal barrier's essential genes, such as hyaluronic acid synthase 3 (Has3), involucrin (IVL), loricrin (LOR), and claudin-1 (CLD1) was investigated using qRT-PCR. Ceramide content was measured by ELISA, with retinoic acid (R.A.) and amarogentin (AMA) serving as positive controls. RESULTS ROC significantly elevated HAS3 gene expression in HEKn cells, especially at 10 ppm, indicating potential advantages for skin hydration in young infants. IVL increased at first but decreased as ROC concentrations increased. LOR was upregulated at lower ROC concentrations but reduced at higher doses. CLD1 gene expression increased considerably in HEKn but reduced with increasing ROC doses. Ceramide concentration increased somewhat but not significantly at 10 ppm. CONCLUSION ROC shows potential in altering keratinocyte gene expression, with unique responses in HEKn and TIKC from young donors. While changes in ceramide content were insignificant, these results help to comprehend ROC's multiple effects on young children's skin.
Collapse
Affiliation(s)
- Thuy‐Tien Thi Trinh
- Department of Plastic and Reconstructive SurgerySeoul National University Bundang HospitalSeongnamRepublic of Korea
| | | | - Jee‐Eun Yang
- Department of Plastic and Reconstructive SurgerySeoul National University Bundang HospitalSeongnamRepublic of Korea
- Korean Institute of Nonclinical StudySeongnamRepublic of Korea
| | | | - Pham Ngoc Chien
- Department of Plastic and Reconstructive SurgerySeoul National University Bundang HospitalSeongnamRepublic of Korea
- Korean Institute of Nonclinical StudySeongnamRepublic of Korea
| | - Linh Thi Thuy Le
- Department of Plastic and Reconstructive SurgerySeoul National University Bundang HospitalSeongnamRepublic of Korea
- Department of Biomedical ScienceCollege of MedicineSeoul National UniversitySeoulRepublic of Korea
| | - Nguyen Ngan‐Giang
- Department of Plastic and Reconstructive SurgerySeoul National University Bundang HospitalSeongnamRepublic of Korea
- Department of Medical Device DevelopmentCollege of MedicineSeoul National UniversitySeoulRepublic of Korea
| | - Pham Thi Nga
- Department of Plastic and Reconstructive SurgerySeoul National University Bundang HospitalSeongnamRepublic of Korea
- Korean Institute of Nonclinical StudySeongnamRepublic of Korea
| | - Sun‐Young Nam
- Department of Plastic and Reconstructive SurgerySeoul National University Bundang HospitalSeongnamRepublic of Korea
| | - Chan‐Yeong Heo
- Department of Plastic and Reconstructive SurgerySeoul National University Bundang HospitalSeongnamRepublic of Korea
- Korean Institute of Nonclinical StudySeongnamRepublic of Korea
- Department of Medical Device DevelopmentCollege of MedicineSeoul National UniversitySeoulRepublic of Korea
| |
Collapse
|
4
|
Falckenhayn C, Bienkowska A, Söhle J, Wegner K, Raddatz G, Kristof B, Kuck D, Siegner R, Kaufmann R, Korn J, Baumann S, Lange D, Schepky A, Völzke H, Kaderali L, Winnefeld M, Lyko F, Grönniger E. Identification of dihydromyricetin as a natural DNA methylation inhibitor with rejuvenating activity in human skin. FRONTIERS IN AGING 2024; 4:1258184. [PMID: 38500495 PMCID: PMC10944877 DOI: 10.3389/fragi.2023.1258184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 07/13/2023] [Accepted: 12/12/2023] [Indexed: 03/20/2024]
Abstract
Changes in DNA methylation patterning have been reported to be a key hallmark of aged human skin. The altered DNA methylation patterns are correlated with deregulated gene expression and impaired tissue functionality, leading to the well-known skin aging phenotype. Searching for small molecules, which correct the aged methylation pattern therefore represents a novel and attractive strategy for the identification of anti-aging compounds. DNMT1 maintains epigenetic information by copying methylation patterns from the parental (methylated) strand to the newly synthesized strand after DNA replication. We hypothesized that a modest inhibition of this process promotes the restoration of the ground-state epigenetic pattern, thereby inducing rejuvenating effects. In this study, we screened a library of 1800 natural substances and 640 FDA-approved drugs and identified the well-known antioxidant and anti-inflammatory molecule dihydromyricetin (DHM) as an inhibitor of the DNA methyltransferase DNMT1. DHM is the active ingredient of several plants with medicinal use and showed robust inhibition of DNMT1 in biochemical assays. We also analyzed the effect of DHM in cultivated keratinocytes by array-based methylation profiling and observed a moderate, but significant global hypomethylation effect upon treatment. To further characterize DHM-induced methylation changes, we used published DNA methylation clocks and newly established age predictors to demonstrate that the DHM-induced methylation change is associated with a reduction in the biological age of the cells. Further studies also revealed re-activation of age-dependently hypermethylated and silenced genes in vivo and a reduction in age-dependent epidermal thinning in a 3-dimensional skin model. Our findings thus establish DHM as an epigenetic inhibitor with rejuvenating effects for aged human skin.
Collapse
Affiliation(s)
| | - Agata Bienkowska
- Beiersdorf AG, Research and Development, Hamburg, Germany
- Institute for Bioinformatics, University Medicine Greifswald, Greifswald, Germany
| | - Jörn Söhle
- Beiersdorf AG, Research and Development, Hamburg, Germany
| | - Katrin Wegner
- Beiersdorf AG, Research and Development, Hamburg, Germany
| | - Guenter Raddatz
- Division of Epigenetics, DKFZ-ZMBH Alliance, German Cancer Research Center, Heidelberg, Germany
| | - Boris Kristof
- Beiersdorf AG, Research and Development, Hamburg, Germany
| | - Dirk Kuck
- Division of Epigenetics, DKFZ-ZMBH Alliance, German Cancer Research Center, Heidelberg, Germany
| | - Ralf Siegner
- Beiersdorf AG, Research and Development, Hamburg, Germany
| | - Ronny Kaufmann
- Beiersdorf AG, Research and Development, Hamburg, Germany
| | - Julia Korn
- Beiersdorf AG, Research and Development, Hamburg, Germany
| | - Sascha Baumann
- Beiersdorf AG, Research and Development, Hamburg, Germany
| | - Daniela Lange
- Beiersdorf AG, Research and Development, Hamburg, Germany
| | | | - Henry Völzke
- Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany
| | - Lars Kaderali
- Institute for Bioinformatics, University Medicine Greifswald, Greifswald, Germany
| | - Marc Winnefeld
- Beiersdorf AG, Research and Development, Hamburg, Germany
| | - Frank Lyko
- Division of Epigenetics, DKFZ-ZMBH Alliance, German Cancer Research Center, Heidelberg, Germany
| | - Elke Grönniger
- Beiersdorf AG, Research and Development, Hamburg, Germany
| |
Collapse
|
5
|
Jiang F, Wu Y, Liu Z, Hong M, Huang Y. Synergy of GHK-Cu and hyaluronic acid on collagen IV upregulation via fibroblast and ex-vivo skin tests. J Cosmet Dermatol 2023; 22:2598-2604. [PMID: 37062921 DOI: 10.1111/jocd.15763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Revised: 03/20/2023] [Accepted: 03/27/2023] [Indexed: 04/18/2023]
Abstract
INTRODUCTION GHK-Cu and HA are two commonly used skin care ingredients, both of which were reported to enhance collagen synthesis. This work aims to investigate their co-effect on collagen regulation. MATERIALS AND METHODS In cell experiments, human dermal fibroblasts were treated by a series of GHK-Cu and HA combinations, and the expressions of collagen I, IV, and VII were measured by qRT-PCR. The best formula screened out from cell experiments were further studied by ex-vivo skin model, and the content of collagen IV was quantified by immunofluorescence method. RESULTS The combination GHK-Cu and HA was found to promote the generation of collagen I, IV, and VII. Especially, they form a synergy on collagen IV. At the ratio of 1:9, GHK-Cu and LMW HA deliver the strongest effect to elevate collagen IV synthesis by 25.4 times in cell test and 2.03 times in ex-vivo skin test. CONCLUSION The co-effect of GHK-Cu and HA was revealed. Their synergy brings an insight to anti-aging technology: choosing proper molecular weight of HA and managing its ratio with GHK-Cu could enhance DEJ health via stimulating collagen IV synthesis.
Collapse
Affiliation(s)
- Fangru Jiang
- Bloomage Biotechnology Co., Ltd, Jinan, Shandong, China
| | - Yanan Wu
- Bloomage Biotechnology Co., Ltd, Jinan, Shandong, China
| | - Zhe Liu
- Bloomage Biotechnology Co., Ltd, Jinan, Shandong, China
| | - Minhua Hong
- Zhejiang Peptites Biotech Co., Ltd, Shaoxing, Zhejiang, China
| | - Yi Huang
- Zhejiang Peptites Biotech Co., Ltd, Shaoxing, Zhejiang, China
| |
Collapse
|
6
|
Li C, Xu B, Song H, Xu Y, Shi LZ, Chen XQ, Song ZC. Calcium dobesilate prevents PLD-induced hand-foot syndrome by alleviating capillary endothelial tight junction injury via the HA/CD44 pathway. Am J Cancer Res 2023; 13:3234-3245. [PMID: 37559988 PMCID: PMC10408487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Accepted: 07/12/2023] [Indexed: 08/11/2023] Open
Abstract
Pegylated liposomal doxorubicin (PLD) has excellent therapeutic efficacy in the treatment of cancers, but can cause serious adverse reactions such as hand-foot syndrome (HFS). Our previous research suggests that both PLD-induced HFS may be associated with injury to tight junctions (TJs) in the skin and that calcium dobesilate (CaD) can alleviate HFS. However, the underlying molecular mechanism is not well understood. Here, we created an in vitro PLD-treated model using Human Microvascular Endothelial Cell line-1 (HMEC-1) and an in vivo HFS rat model to investigate the underlying pathways. Treatment with PLD increased the expression of HYAL-1, CD44, and hyaluronic acid (HA) concentration, while reducing ZO-1 and Claudin-5 expression. Moreover, PLD treatment induced the degradation of higher molecular weight HA to its lower molecular weight counterpart, elevating the permeability of both HEMC-1 cell membranes and rat paw skin capillaries. AD-01 (CD44 inhibitor) inhibited the effect of PLD on the expression of ZO-1 and Claudin-5. Furthermore, CaD treatment suppressed the expression of HYAL-1 and CD44, mitigated HA degradation, and enhanced the expression of ZO-1 and Claudin-5. This resulted in decreased permeability in HEMC-1 cells and rat skin capillaries. In summary, our data suggest that PLD may promote the destruction of TJs via the HA/CD44 pathway, thereby leading to HFS through increased skin permeability and exacerbated doxorubicin extravasation. Moreover, CaD can inhibit this pathway, offering a potential therapeutic avenue to alleviate HFS.
Collapse
Affiliation(s)
- Chao Li
- Department of Breast Center, The Fourth Hospital of Hebei Medical UniversityShijiazhuang 050000, Hebei, P. R. China
| | - Bin Xu
- Department of Breast Center, The Fourth Hospital of Hebei Medical UniversityShijiazhuang 050000, Hebei, P. R. China
| | - Heng Song
- Department of Breast Center, The Fourth Hospital of Hebei Medical UniversityShijiazhuang 050000, Hebei, P. R. China
| | - Yu Xu
- Department of Breast Center, The Fourth Hospital of Hebei Medical UniversityShijiazhuang 050000, Hebei, P. R. China
| | - Ling-Zi Shi
- Department of Breast Center, The Fourth Hospital of Hebei Medical UniversityShijiazhuang 050000, Hebei, P. R. China
| | - Xiao-Qing Chen
- Department of Breast Center, The Fourth Hospital of Hebei Medical UniversityShijiazhuang 050000, Hebei, P. R. China
| | - Zhen-Chuan Song
- Department of Breast Center, The Fourth Hospital of Hebei Medical UniversityShijiazhuang 050000, Hebei, P. R. China
- Key Laboratory for Breast Cancer Molecular Medicine of Hebei ProvinceShijiazhuang 050000, Hebei, P. R. China
| |
Collapse
|
7
|
Size matters: differential property of hyaluronan and its fragments in the skin- relation to pharmacokinetics, immune activity and wound healing. JOURNAL OF PHARMACEUTICAL INVESTIGATION 2023. [DOI: 10.1007/s40005-023-00614-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/03/2023]
|
8
|
Hyaluronic Acid Hydrogel Containing Resveratrol-Loaded Chitosan Nanoparticles as an Adjuvant in Atopic Dermatitis Treatment. J Funct Biomater 2023; 14:jfb14020082. [PMID: 36826881 PMCID: PMC9959248 DOI: 10.3390/jfb14020082] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2022] [Revised: 01/14/2023] [Accepted: 01/29/2023] [Indexed: 02/04/2023] Open
Abstract
Atopic dermatitis (AD) is a common disease-causing skin inflammation, redness, and irritation, which can eventually result in infection that drastically impacts patient quality of life. Resveratrol (Res) is a natural phytochemical famed for its excellent anti-inflammatory and antioxidant activities. However, it is poorly bioavailable. Thus, a drug delivery system is needed to enhance in vivo bioactivity. Herein, we report the preparation of hyaluronic acid (HA) hydrogels containing resveratrol-loaded chitosan (CS) nanoparticles, their physicochemical analysis, and their potential therapeutic effects in the treatment of AD. Positively charged CS nanoparticles prepared by tripolyphosphate (TPP) gelation showed sizes ranging from 120 to around 500 nm and Res encapsulation efficiency as high as 80%. Embedding the nanoparticles in HA retarded their hydrolytic degradation and also slowed resveratrol release. Resveratrol released from nanoparticle-loaded hydrogel counteracted the oxidative damage induced by ROS generation in TNF-α/INF-γ-treated human keratinocytes (HaCaT) used as an AD in vitro model. Moreover, pre-treatment with Res@gel reduced secretion and gene expression of proinflammatory cytokines in HaCaT cells. The physicochemical analysis and in vitro assay confirmed that the formulated hydrogel could be considered an efficient and sustained resveratrol delivery vector in AD treatment.
Collapse
|
9
|
Jing P, Luo Y, Wang L, Tan J, Chen Y, Chen Y, Zhang S. An oligomeric hyaluronic acid-GX1 molecular target drug with polyvalent targeting to CD44 and VEGF receptors. BIOMATERIALS ADVANCES 2023; 144:213217. [PMID: 36502748 DOI: 10.1016/j.bioadv.2022.213217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Revised: 11/14/2022] [Accepted: 11/21/2022] [Indexed: 06/17/2023]
Abstract
The off-target toxicity of molecular targeted drug hinders its clinical transformation. Herein, we report a new molecular targeted drug oHA-GX1 constructed by oligomeric hyaluronan (oHA) and peptide GX1 (CGNSNPKSC). The oHA-GX1 can not only suppress the tumor growth by interacting with overexpressed VEGF and CD44 receptors inside tumor tissues, but also reduce the likelihood of off-target toxicity due to the multiple VEGF and CD44 receptors binding sites. The cytotoxicity study shows that the IC50oHA-GX1 against co-SGC-7901 and co-HUVEC cells fell in the range of common cytotoxic drugs. The animal experiment results reveal that the tumor inhibition rate of oHA-GX1 (100 mg/kg) against SGC-7901 tumor-bearing mice were 78.4 %, which was comparable to that of front-line chemotherapy drugs. Also, the cytotoxicity study on normal cells, hemolysis test, hemagglutination assay and the acute toxicity test demonstrate that oHA-GX1 exhibited excellent biosafety. This molecular targeted drug that utilizes the multiple receptor-binding sites to get rid of the side effects caused by off-target paves a new direction for the discovery of anticancer drugs with high efficacy and low adverse effects.
Collapse
Affiliation(s)
- Pei Jing
- College of Biomedical Engineering and National Engineering Research Center for Biomaterials, Sichuan University, 29 Wangjiang Road, Chengdu 610064, China; Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province 646000, China
| | - Yuling Luo
- Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province 646000, China
| | - Liang Wang
- College of Biomedical Engineering and National Engineering Research Center for Biomaterials, Sichuan University, 29 Wangjiang Road, Chengdu 610064, China
| | - Jiangbing Tan
- College of Biomedical Engineering and National Engineering Research Center for Biomaterials, Sichuan University, 29 Wangjiang Road, Chengdu 610064, China
| | - Yun Chen
- MOE International Joint Research Laboratory on Synthetic Biology and Medicines, School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China
| | - Ying Chen
- The State Key Laboratory of Functions and Applications of Medicinal Plants & College of Pharmacy, Guizhou Medical University, University Town, Guian New District, 550025, Guizhou, China
| | - Shiyong Zhang
- College of Biomedical Engineering and National Engineering Research Center for Biomaterials, Sichuan University, 29 Wangjiang Road, Chengdu 610064, China.
| |
Collapse
|
10
|
Juhaščik M, Kováčik A, Huerta-Ángeles G. Recent Advances of Hyaluronan for Skin Delivery: From Structure to Fabrication Strategies and Applications. Polymers (Basel) 2022; 14:polym14224833. [PMID: 36432961 PMCID: PMC9694326 DOI: 10.3390/polym14224833] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 11/04/2022] [Accepted: 11/08/2022] [Indexed: 11/12/2022] Open
Abstract
Hyaluronan (HA) plays a fundamental role in maintaining the homeostasis on skin health. Furthermore, the effect of HA in skin inflammatory diseases is worth studying in the next future. HA and its conjugates change the solubility of active pharmaceutical ingredients, improve emulsion properties, prolong stability, reduce immunogenicity, and provide targeting. HA penetrates to deeper layers of the skin via several mechanisms, which depend on the macromolecular structure and composition of the formulation. The cellular and molecular mechanisms involved in epidermal dysfunction and skin aging are not well understood. Nevertheless, HA is known to selectively activate CD44-mediated keratinocyte signaling that regulates its proliferation, migration, and differentiation. The molecular size of HA is critical for molecular mechanisms and interactions with receptors. High molecular weight HA is used in emulsions and low molecular weight is used to form nanostructured lipid carriers, polymeric micelles, bioconjugates, and nanoparticles. In the fabrication of microneedles, HA is combined with other polymers to enhance mechanical properties for piercing the skin. Hence, this review aims to provide an overview of the current state of the art and last reported ways of processing, and applications in skin drug delivery, which will advocate for their broadened use in the future.
Collapse
Affiliation(s)
- Martin Juhaščik
- Contipro a.s., Dolní Dobrouč 401, 561 02 Dolnί Dobrouč, Czech Republic
- Skin Barrier Research Group, Faculty of Pharmacy in Hradec Králové, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
| | - Andrej Kováčik
- Skin Barrier Research Group, Faculty of Pharmacy in Hradec Králové, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
| | - Gloria Huerta-Ángeles
- Contipro a.s., Dolní Dobrouč 401, 561 02 Dolnί Dobrouč, Czech Republic
- Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Heyrovského Nám. 2, 162 06 Prague, Czech Republic
- Correspondence:
| |
Collapse
|
11
|
Fujikawa M, Sugimoto H, Tamura R, Fujikawa K, Yamagishi A, Ueda Y. Effects of mucopolysaccharide polysulphate on tight junction barrier in human epidermal keratinocytes. Exp Dermatol 2022; 31:1676-1684. [PMID: 35770317 PMCID: PMC9796026 DOI: 10.1111/exd.14637] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2022] [Revised: 06/20/2022] [Accepted: 06/27/2022] [Indexed: 12/30/2022]
Abstract
Tight junctions (TJs) play important roles in epidermal barrier function and their dysfunction is involved in the pathogenesis of various skin diseases, including atopic dermatitis (AD). Mucopolysaccharide polysulphate (MPS) is the active ingredient of a moisturizing agent used to treat xerosis in patients with AD; however, its mechanism of action on TJ barrier function remains unclear. To elucidate the effects of MPS on TJs, adult human epidermal keratinocyte (HEKa) cells were exposed to MPS, subjected to Western blotting and quantitative PCR analyses for the investigation of TJ-related factors. MPS treatment significantly increased the mRNA and protein expression of claudin-1 (CLDN1) and zonula occludens-1, and significantly increased transepithelial electrical resistance (TEER), which indicates TJ integrity. Conversely, the sulphated and non-sulphated glycosaminoglycans, chondroitin sulphate and hyaluronic acid, respectively, had little effect on TEER or the expression of mRNAs or TJ-related proteins. Interestingly, MPS treatment also inactivated the extracellular signal-regulated kinase signalling pathway, which is known to negatively regulate CLDN1 expression. Furthermore, MPS notably improved the reduction in CLDN1 expression and TEER caused by histamine, which is upregulated in the skin of patients with AD and is known to disrupt the TJ barrier function. Taken together, these findings demonstrate that treatment with the moisturizing agent, MPS, can repair TJ dysfunction and could therefore represent a new therapeutic option for treating patients with AD.
Collapse
Affiliation(s)
| | | | - Rie Tamura
- Kyoto R&D Center, Maruho Co., Ltd.KyotoJapan
| | | | | | - Yuhki Ueda
- Kyoto R&D Center, Maruho Co., Ltd.KyotoJapan
| |
Collapse
|